Business Context and Reporting Period
Lisata Therapeutics, Inc. (Lisata) filed a Form 8-K on September 17, 2026, reporting the completion of a merger with Marea Therapeutics, Inc. (Marea) and a concurrent private placement financing. The transaction was structured as a tax-free reorganization where Marea became a wholly-owned subsidiary of Lisata. The filing details the issuance of equity to Marea stockholders and the appointment of new leadership.
Key Financial Metrics and Capital Structure
- Financing Amount: Lisata agreed to sell approximately $225 million in Series C Non-Voting Convertible Preferred Stock (PIPE Securities) to investors.
- Equity Issuance (Merger): Lisata issued 1,793,129 shares of Common Stock and 211,365.213 shares of Series C Preferred Stock to Marea stockholders.
- Equity Issuance (Financing): Lisata issued 150,867.995 shares of Series C Preferred Stock to PIPE investors.
- Conversion Terms: Each share of Series C Preferred Stock is convertible into 1,000 shares of Common Stock, subject to stockholder approval and beneficial ownership limitations.
- Post-Transaction Ownership (Fully Diluted):
- Pre-transaction Lisata stockholders: ~2.39%
- Former Marea equityholders: ~59.54%
- PIPE Investors: ~38.07%
- Financial Statements: The filing does not provide revenue, profit, cash flow, or debt metrics. Financial statements for Marea and pro forma information are expected to be filed in an amendment (Form 8-K/A) by November 12, 2026.
Material Changes and Corporate Actions
- Acquisition: Lisata acquired Marea via a two-step merger. Marea stockholders received a mix of Common Stock and Series C Preferred Stock.
- Leadership Changes:
- Ted W. Love, M.D. was appointed to the Board of Directors.
- Josh Lehrer, M.D. was appointed President and Chief Operating Officer (COO).
- David J. Mazzo, Ph.D. resigned as President but retained his role as Chief Executive Officer (CEO).
- Compensation: Dr. Lehrer's new compensation package includes a $475,000 annual base salary and a target annual cash bonus of 40% of base salary. Severance provisions include 12 months of base salary plus COBRA coverage for termination without Cause or resignation for Good Reason.
- Lock-up Agreements: Certain officers, directors, and stockholders of both companies are subject to a 180-day lock-up on the sale or transfer of shares.
Outlook, Risks, and Contingencies
- Stockholder Approval Required: Lisata must hold a stockholders' meeting to approve:
- Conversion of Series C Preferred Stock to Common Stock.
- A "change of control" under Nasdaq rules.
- Potential charter amendments to authorize additional shares or effectuate a reverse stock split to maintain Nasdaq listing standards.
- Registration Rights: Lisata agreed to file a resale registration statement (Form S-3) for Marea stockholders and PIPE investors by the later of 45 days post-financing or the filing of the 8-K/A containing Marea's financials.
- Forward-Looking Risks: The filing includes standard disclaimers regarding the uncertainty of stockholder approval, the timing of registration statement effectiveness, and the successful closing of the financing.
- Unusual Items: The transaction involves a significant dilution of pre-transaction Lisata shareholders, reducing their ownership from a controlling interest to approximately 2.39% on a fully diluted basis post-financing.
Investor Verification Checklist
- Verify the outcome of the upcoming stockholders' meeting regarding the Conversion Proposal and Change in Control Proposal.
- Review the upcoming Form 8-K/A (due by November 12, 2026) for Marea's audited financial statements and pro forma combined financial information.
- Confirm the final closing of the $225 million PIPE financing and the issuance of Series C Preferred Stock.
- Monitor Nasdaq compliance status, specifically regarding the potential need for a reverse stock split to maintain listing standards.
- Assess the strategic fit and pipeline integration of Marea Therapeutics with Lisata's existing operations.